A phase I study of GOVX-B11 to evaluate the safety and immunogenicity of a prime-boost regimen of GOVX-B11 with and without two additional protein boosts

Trial Profile

A phase I study of GOVX-B11 to evaluate the safety and immunogenicity of a prime-boost regimen of GOVX-B11 with and without two additional protein boosts

Planning
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs GOVX-B11 (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Nov 2017 New trial record
    • 09 Nov 2017 According to a GeoVax Labs media release, this trial will be conducted by HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Diseases (NIAID) and the company anticipates to initiate this trial in mid-2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top